A Phase II Trial to Evaluate Progression-Free Survival in Integrating Local Ablative Therapy with First-Line Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer

Cancer Council Victoria0 个研究点目标入组 50 人开始时间: 2021年9月8日最近更新: 2024年8月5日

适应症

试验速览

暂无简介。

•-Metastatic colorectal adenocarcinoma that is not amenable to potentially curative surgery.
•-Primary tumour must be controlled if the primary is intact, with no evidence of progression at primary site prior to study entry
•-Imaging demonstrating ongoing treatment benefit (partial response or stable disease as per RECIST criteria) after 3-6 months of standard first-line systemic treatment.
•-3 to 10 metastatic lesions detected on CT +/- FDG-PET scan prior to first line systemic treatment AND on screening FDG-PET and CT scans:
•o maximum of 3 lesions per organ except for the liver and lung
•o maximum of 5 lesions in the lung
•o no limit to number of liver lesions provided all are amenable to LAT
•o maximum of 3 involved organs including a maximum of 2 lymph node stations.
•-All lesions can be safely treated by LAT as determined by multidisciplinary team meeting.

•-Concurrent or previous other malignancy within 2 years of study entry, except curatively treated basal or squamous cell skin cancer, prostate intraepithelial neoplasm, carcinoma in-situ of the cervix, Bowen’s disease or prostate cancer with a Gleason score =6.
•-Presence of brain, peritoneal, omental or ovarian metastases
•-Malignant pleural effusion or ascites.

发起方